Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Buffalo Berry (Shepherdia argentea) delivers exceptionally high concentrations of proanthocyanidins (505 mg/100g), ascorbic acid (209 mg/100g), and unique hydrolyzable tannins (shephagenins A and B) that produce 5-fold greater DPPH radical scavenging activity than sea buckthorn while inhibiting HIV-1 reverse transcriptase and pro-inflammatory cytokines IL-1β and COX-2. The fruit's synergistic combination of lycopene, methyl-buffalogenin, and polyphenolic compounds supports cardiovascular, immune, and metabolic health through multi-pathway antioxidant defense, NF-κB suppression, and endothelial nitric oxide modulation—though no large-scale randomized clinical trials specific to buffalo berry supplementation currently exist in the PubMed literature, underscoring the need for rigorous human intervention studies similar in design to those conducted in major trials such as the Women's Health Initiative (Manson et al., JAMA, 2024; PMID 38691368).
Reported Benefits (Provisional)
Origin & History
Buffalo Berry (Shepherdia argentea) is a deciduous shrub native to North America, particularly the northern Great Plains, Rocky Mountain regions, and boreal areas of the U.S. and Canada. It thrives in diverse environments, from prairies to riverbanks. This resilient fruit is valued in functional nutrition for its potent antioxidant and nutrient profile.
Research Narrative (Provisional)
While no large-scale randomized controlled trials have been conducted specifically on Shepherdia argentea in humans, the methodological frameworks established by landmark trials inform best practices for future buffalo berry research. The Women's Health Initiative Randomized Trials review (Manson JE et al., JAMA, 2024; PMID 38691368) underscores the importance of rigorous dietary intervention trial design for evaluating plant-derived bioactive compounds in cardiovascular and chronic disease outcomes. Precision biospecimen handling protocols detailed by Compton et al. (Arch Pathol Lab Med, 2019; PMID 31329478) are directly applicable to ensuring molecular integrity when analyzing buffalo berry's labile polyphenolic and ascorbic acid fractions in research settings. Current evidence for buffalo berry's bioactivity derives primarily from in vitro DPPH/ABTS radical scavenging assays, enzyme inhibition studies on shephagenins A and B against HIV-1 reverse transcriptase, and compositional analyses confirming its superior proanthocyanidin and vitamin C density relative to comparable berries including sea buckthorn.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Dietary fiber. - Vitamins C and A. - Potassium, Magnesium, and Calcium. - Lycopene, Flavonoids, and Polyphenols.
Reported Mechanism (Provisional)
Buffalo berry's proanthocyanidins (oligomeric and polymeric flavan-3-ols at 505 mg/100g) and L-ascorbic acid (209 mg/100g) neutralize reactive oxygen species through direct hydrogen atom transfer in DPPH and ABTS radical scavenging pathways, yielding antioxidant capacity approximately 5-fold higher than sea buckthorn. The fruit's unique hydrolyzable tannins—shephagenins A and B—competitively inhibit HIV-1 reverse transcriptase and suppress the NF-κB signaling cascade, downregulating transcription of pro-inflammatory mediators including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and cyclooxygenase-2 (COX-2). Lycopene and carotenoid constituents quench singlet oxygen and modulate endothelial nitric oxide synthase (eNOS) activity, promoting vasodilation and supporting cardiovascular function. Additionally, dietary fiber and phenolic acids in the berry matrix interact with gut microbiota to produce short-chain fatty acids (SCFAs) such as butyrate, further attenuating systemic inflammation via HDAC inhibition and GPR43/GPR109A receptor activation.
Clinical Narrative (Provisional)
Current evidence derives exclusively from in vitro laboratory studies rather than human clinical trials. Studies demonstrate crude extracts achieving 78% IL-1β inhibition and 47% COX-2 suppression at 100 μg/mL concentrations, with enzyme inhibition exceeding 70% at 5 μg/mL doses. Canadian buffaloberry extracts showed growth inhibition against mastocytoma cell lines in laboratory conditions. While promising, the lack of human clinical data limits definitive therapeutic recommendations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.